Last update: 04.02.2019
From left: Robert Lyle, Trine Rounge, Magnus Leithaug, Hilde Langseth, Sinan Ugur Umu, Marianne Lauritzen and Cecilie Bucher-Johannessen
Serum contain many types of RNA molecules such as protein-coding messenger RNAs (mRNAs), miRNAs, piRNAs, transfer RNAs (tRNAs) and other miscellaneous non-coding RNA molecules. Regulatory ncRNAs, and in particullar microRNAs (miRNA), have been implicated in cancer and many other diseases and are thus promising biomarkers.
We have initiated two large small non-coding RNA cancer biomarker projects. These projects are led by the Cancer Registry of Norway (CRN) , and in close collaboration with the Norwegian Sequencing Center (NSC) at Oslo University Hospital (OUS), Saarland University, and bioinformatics core facilities at the University of Oslo.
Pre-diagnostic samples from the Janus Serum Bank (JSB), cancer data from the registry and health survey data provides a unique oppertunity to discover early detection cancer biomarkers.
The project is funded by the Research Council of Norway.
About 30.000 Norwegians are diagnosed with cancer annually and cancer is the second leading cause of death overall in Norway.
Colorectal cancer is one of the most common cancers and has increased rapidly in Norway since the 1960s in both men and women. Symptoms from colon cancer often appear at a late stage, when prognosis is uncertain or poor.
Similarly, lung cancer is the predominant cause of cancer-related death in men and women, and the incidence rates among women are still increasing. Due to lack of efficient strategies for screening or early diagnosis, the prognosis is generally poor.
Aim of research
The overall research aim is to investigate sncRNAs as early detection biomarkers. The long-term goal is to exploit such biomarkers in cancer screening.
We have produced sncRNA expression profiles from more than 2000 cancer cases and 600 healthy controls using pre-diagnostic serum samples from the Janus Serum Bank, on an Illumina HiSeq platform at NSC.
Our data set contain quality assured expression profiles that can be accessed by national and international research groups. We have reached an average sequence depth of 18 million sequences, and identified more than 600 unique miRNAs per sample in addition to other noncoding RNAs.
Overview of ongoing Projects
Genome-wide miRNA profiling in prediagnostic samples from Janus Serum Bank for early diagnosis, improved therapy & surveillance of cancer
Genetic susceptibility to testicular cancer
miRNA signatures in patients with colon cancer, breast cancer and lung cancer
Identification of biomarkers for gallbladder cancer risk prediction- Towards personalized prevention of an orphan disease
Core Facility Leader, Robert Lyle, PhD
Lab Technician, Magnus Leithaug, BSc
Chair for Clinical Bioinformatics, Andreas Keller, PhD
Institute of Human Genetics, Eckart Meese, PhD
Institute for Cancer Research at Oslo University Hospital:
Department of Tumor Biology and Bioinformatics Core Facility, Prof. Eivind Hovig, PhD
Department of Molecular Oncology, Prof. Ragnhild A. Lothe, PhD
Department of Oncology, Assoc. Prof Åslaug Helland, MD
Institute for Cancer Research, Bastian Fromm, PhD, Post Doc
Oslo and Akershus University College of Applied Sciences
Faculty of Health Sciences, Trine B. Haugen
University of Heidelberg
Department of Biometry and Informatics, Prof. Justo Lorenzo Bermejo, PhD
Department of Medical Epidemiology and Biostatistics, Prof. Fredrik Wiklund
German Cancer Research Centre
Division of Cancer Epidemiology, Prof. Rudolf Kaaks
School of Public Health, Imperial College London
Prof. Paolo Vineis, MD, MPH, FFPH
Chair of Environmental Epidemiology
MRC/PHE Centre for Environment and Health
How to get access to data
All research projects that includes information and/or biological material from Janus serum bank must comply with the EU’s General Data Protection Regulation (GDPR). This means that the processing must have approval from the Regional Committee for Medical Research in Norway (REC). Furthermore the processing needs legal basis according to GDPR Article 6 and 9. The applicant must have considered the need for a Data Protection Impact Assessment (DPIA) according to GDPR article 35. The applicant must prove that these requirements have been met before the data can be made available. Disclosure of information and/or biological material to countries outside the EU requires that the conditions in GDPR are met. For more information email miRJanus[a]kreftregisteret.no.
Rounge TB, Umu SU, Lyle R, Langseth H, et al 2018. "Circulating small non-coding RNAs associated with age, sex, smoking, body mass and physical activity".
Umu SU, Langseth H, Bucher-Johannessen C, Lauritzen M, Leithaug M, Lyle R, Rounge TB, et al 2017. "A comprehensive profile of circulating RNAs in human serum"
Fehlmann T, Langseth H, Rounge TB, Umu SU, et al 2017. "A high-resolution map of the human small non-coding transcriptome".
Keller A, Rounge TB, Langseth H, et al 2017. "Sources to variability in circulating human miRNA signatures".
Rounge TB, Langseth H, Lauritzen M, et al. 2015. "microRNA Biomarker Discovery and High-Throughput DNA Sequencing Are Possible Using Long-term Archived Serum Samples".
Keller A, Langseth H, et al. 2011. "Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis".